Investment Management Associates Inc. ADV Trims Stock Holdings in Solventum Corporation $SOLV

Investment Management Associates Inc. ADV lowered its stake in Solventum Corporation (NYSE:SOLV) by 34.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 117,305 shares of the company’s stock after selling 62,792 shares during the quarter. Solventum comprises about 1.8% of Investment Management Associates Inc. ADV’s holdings, making the stock its 18th biggest position. Investment Management Associates Inc. ADV’s holdings in Solventum were worth $7,660,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Hilltop National Bank grew its stake in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after acquiring an additional 129 shares during the period. CrossGen Wealth LLC bought a new stake in Solventum during the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC purchased a new position in Solventum during the third quarter valued at approximately $25,000. Clearstead Trust LLC lifted its holdings in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after purchasing an additional 228 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SOLV. Stifel Nicolaus reduced their price objective on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. BMO Capital Markets assumed coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target for the company. KeyCorp boosted their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler cut their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Wells Fargo & Company decreased their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $81.91.

Solventum Stock Performance

SOLV opened at $81.36 on Monday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The stock has a market capitalization of $14.09 billion, a price-to-earnings ratio of 9.97, a PEG ratio of 1.25 and a beta of 0.66. The company has a fifty day moving average of $77.09 and a 200 day moving average of $74.23. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $88.20.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business’s revenue was down 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.